Immigrant Medicaid enrollees' personal data given to immigration officials
The Trump administration has reportedly given the personal data of millions of Medicaid enrollees to the Department of Homeland Security (DHS), as part of President Trump's sweeping deportation agenda.
Officials at the Centers for Medicare and Medicaid Services handed over a dataset on Medicaid enrollees in California, Illinois, Washington state and Washington D.C., according to the Associated Press. All these states allow non-U.S. citizens to receive Medicaid benefits.
The AP obtained an internal memo and emails showing that two top advisors to Health Secretary Robert F. Kennedy Jr. ordered the data sharing and gave CMS 45 minutes to comply. The data includes names, addresses, social security numbers and immigration status.
Gov. Gavin Newsom (D), in a statement to the AP, said the 'potential data transfer' was 'extremely concerning, and if true, potentially unlawful, particularly given numerous headlines highlighting potential improper federal use of personal information and federal actions to target the personal information of Americans.'
Immigration and Customs Enforcement are aiming to deport 3,000 undocumented immigrants per day, according to White House aide Stephen Miller.
The administration has frequently threatened states that don't cooperate with Trump's immigration policies. Trump this week suggested he'd like to see Newsom arrested over his response to protests in Los Angeles against federal workplace immigration sweeps.
CMS announced on May 27 that it was 'increasing federal oversight to stop states from misusing federal Medicaid dollars to cover health care for individuals who are in the country illegally,' in line with President Trump's executive order 'Ending Taxpayer Subsidization of Open Borders,' signed on Feb. 19.
'Medicaid funds must serve American citizens in need and those legally entitled to benefits,' CMS Deputy Administrator Drew Snyder said at the time. 'If states cannot or will not comply, CMS will step in.'
According to the AP, Medicaid Deputy Director Sara Vitolo wrote in a memo that this move could violate federal laws such as the Social Security Act and Privacy Act of 1974.
The growing tension between state and federal authorities over Trump's deportation push was on full display Thursday when Democratic governors appeared for a House Oversight hearing.
Last month, a judge allowed ICE to have access to Internal Revenue Service (IRS) data to facilitate mass deportations, which overturned decades of precedent in handling of personal data between agencies.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
12 minutes ago
- Bloomberg
Zelenskiy Says ‘American Decisiveness' Key to Pressuring Putin
Ukraine needs clarity from the US about steps to put pressure on Russia toward a ceasefire, since European support will also depend on it, President Volodymyr Zelenskiy said ahead of the G7 meeting in Canada, where he hopes to meet President Donald Trump. 'I very much want Trump to take strong steps,' Zelenskiy told reporters in Kyiv late Friday. 'It's important for us that Trump stops Putin with sanctions and other steps. This will give a signal to all of Europe, everyone will unite, and we will have this chance.'
Yahoo
22 minutes ago
- Yahoo
There's a new blood test for Alzheimer's. Here's everything you need to know.
When you buy through links on our articles, Future and its syndication partners may earn a commission. The U.S. Food and Drug Administration (FDA) recently cleared a blood test that detects signs of Alzheimer's disease in the brain, according to multiple studies. This is the first-ever blood test available for this common form of dementia. Here's how the new blood test works and why it could be useful to patients. Alzheimer's disease is on the rise, in part because the age group most prone to dementia is growing larger. In the U.S., an estimated 7.2 million Americans ages 65 and older are living with Alzheimer's dementia in 2025. The percentage of affected people increases with age: About 5% of people ages 65 to 74 have Alzheimer's, compared with more than 33% of people ages 85 and older. At the point when a doctor has verified that a patient has cognitive decline, the blood test can be used in place of standard tests to see if they likely have Alzheimer's. Previously, gold-standard methods of diagnosing Alzheimer's have been more invasive and expensive, involving positron emission tomography (PET) scans, which use radioactive substances; and lumbar punctures, (also called spinal taps) during which a clinician uses a needle to sample spinal fluid from the low back. Clinicians also sometimes use MRIs or CT scans to rule out other causes of cognitive decline. The new test measures the ratio of two proteins in human blood, and this ratio correlates with the presence or absence of amyloid plaques, a primary sign of Alzheimer's found in the brain. For people experiencing memory lapses that might be due to Alzheimer's, the first step is to see their primary care physician (PCP), who should do a cognitive test. If there are signs of cognitive impairment, the patient would then be referred to a neurologist for an in-depth evaluation. Both dementia specialists and PCPs will be able to order this blood test to help with diagnosis, said Dr. Gregg Day, a neurologist with the Mayo Clinic in Jacksonville, Florida; Day led a study of the blood test published in June in the Journal of the Alzheimer's Association. A study published in 2024 in JAMA found that whether the test was ordered by a PCP or specialist, it was equally accurate at confirming suspected Alzheimer's diagnoses. PCPs could use the test results to decide whether to refer patients to a specialist, who could prescribe treatments such as lecanemab or donanemab, Day said. Or the PCP could personally prescribe a medicine like donepezil, which can help improve mental function in Alzheimer's. With FDA clearance, Medicare and private health insurance providers alike are expected to cover the new blood test, Day said. The test — called the "Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio" — is intended for people ages 55 and older who show signs and symptoms of cognitive decline that have been confirmed by a clinician. The test is designed for the early detection of amyloid plaques associated with Alzheimer's disease. (Amyloid plaques are unusual clumps found between brain cells and made up of a type of protein called beta-amyloid.) Related: Man nearly guaranteed to get early Alzheimer's is still disease-free in his 70s — how? Early detection is important, said Dr. Sayad Ausim Azizi, clinical chief of behavioral neurology and memory disorders at the Yale School of Medicine. That's because the Alzheimer's brain is like a rusty engine — the plaque is like rust settling onto the engine, interfering with the wheels' ability to turn, Azizi told Live Science. There are FDA-approved treatments that act like oil, helping the wheels to turn, but the medication does not remove the rust itself, he said. Available therapies can slow down the degradation of the brain by about 30% to 40%, studies show, so the patient can retain function for longer. "If you're driving now and living independently and you don't take the medicine, it's likely in five years you won't be able to do all these things," Azizi said, providing a hypothetical example. "If you take the medicine, the five years are extended to eight." If adopted as intended, the new blood test could help more people access these treatments sooner. The test is not recommended for the purposes of screening the general population. It is intended only for people who have been found by a doctor to exhibit signs of Alzheimer's disease, Day and Azizi emphasized. Some amount of amyloid is present in the brain during healthy aging, so its presence doesn't guarantee someone will later have Alzheimer's. If the test detects signs of amyloid plaques 20 years before any cognitive symptoms surface, Azizi explained, it would not make sense to treat the patient at that time. "The treatments are not 100% benign," he added. To receive lecanemab, for example, patients must be able to receive an infusion every two weeks at first and every four weeks later on; donanemab is given every four weeks. Both medications can come with infusion-related reactions, such as headache, nausea and vomiting. Rarely, the treatment donanemab can cause life-threatening allergic reactions, and both lecanemab and donanemab have been tied to rare cases of brain swelling or bleeding in the brain. These latter side effects are related to "amyloid-related imaging abnormalities," which are structural abnormalities that appear on brain scans. The new test can give false positives, meaning a person can potentially test positive when they don't actually have Alzheimer's. That's because the signs of amyloid that the tests look for can be tied to other conditions. For instance, amyloid buildup in the brain could be a sign the kidneys are not functioning optimally, Day said, so he recommends also doing a blood test for kidney function when ordering the Alzheimer's blood test. The Mayo Clinic study included about 510 people, 246 of whom showed cognitive decline; the blood test confirmed 95% of those with cognitive symptoms had Alzheimer's. About 5.3% of cases showed a false negative on the blood test, while 17.6% of cases gave a false positive, Day said. Most of the false-positive patients still had Alzheimer's-like changes in their brains, but their symptoms were ultimately attributed to other diseases, such as Lewy body dementia, Day said. The Mayo study found that the blood test helped doctors distinguish Alzheimer's from these other forms of dementia. As is true of many clinical trials, evaluations of the test have primarily included populations that are healthier than average, Day said. These individuals are not only healthier at baseline, but are more likely to have health insurance and be white and non-Hispanic. So when the blood test is used in a broader population, there may be people with sleep apnea or kidney disease who test positive despite not having Alzheimer's, Day said. Some people with these health problems may also experience memory issues or cognitive impairment that's not caused by Alzheimer's disease. If the blood test points to amyloid buildup, doctors could order additional tests and ask patients about their sleep to help rule out these other possibilities. RELATED STORIES —Could vaccines prevent and treat Alzheimer's disease? —Study unravels whole new layer of Alzheimer's disease —Alzheimer's comes in at least 5 distinct forms, study reveals The test will give researchers a more precise idea of how a patient's clinical symptoms relate to the findings on their blood test, Azizi said. "It's a great way of using a biomarker [measurable sign of disease] in the blood to make an earlier diagnosis to give a drug" to slow disease progression, he said. Azizi added that this blood test could help track whether a treatment for Alzheimer's disease is working, which would be useful both for patients receiving approved medicines and those in trials of new drugs. Looking forward, researchers will also be able to evaluate how well blood-based testing works in more diverse populations, Day noted. This article is for informational purposes only and is not meant to offer medical advice.
Yahoo
22 minutes ago
- Yahoo
Protests live updates: Marines on duty in Los Angeles 1 week into city's protests
Saturday marks the first full day of Marines on duty in Los Angeles, one week after protests against Immigration and Customs Enforcement raids ignited in LA and spread to other cities across the U.S., including New York City, San Francisco, Boston, and Austin, Texas. President Donald Trump deployed about 4,000 National Guardsmen and 700 Marines to LA this week, against the wishes of LA Mayor Karen Bass and California Gov. Gavin Newsom. A federal appeals court Thursday delayed an order requiring the Trump administration to return control of the National Guard to Newsom, dealing the administration a temporary reprieve to what would have been a major reversal of its policy on the protests. President Donald Trump has painted a bleak picture of Los Angeles since protests against Immigration and Customs Enforcement raids broke out over the has repeatedly said that the city was going to burn without the intervention of the military and that there were paid "insurrectionists" and "criminal invaders" seizing the city, which had devolved into "anarchy."Local leaders, however, present a more complex picture of the scene on the here to read began their deployment in Los Angeles on Friday, with some spotted guarding the Wilshire Federal of "No Kings Day" protests are set to be held throughout the U.S. and abroad on Saturday to protest President Donald Trump's administration and to counterprogram the military Levin, the co-executive director of progressive organizing group Indivisible, told ABC News on Thursday there are now more than 2,000 events planned "just about everywhere, everywhere but downtown D.C. -- intentionally so."According to Levin, the organizers did not want to give Trump a rationale to retaliate against peaceful protests in D.C. or to say that the protesters were protesting the here to read more.
